 SENDERRA <i>Specialty Pharmacy</i> 3712 E. Plano Parkway, Ste. 200 Plano, TX 75074 <i>This prescription form is to be sent & received via fax</i>	Pediatric Atopic Dermatitis Enrollment Form A-H Physician Offices Call: 855-460-7928 Fax: 888-777-5645	Prescriber: _____ Supervising Physician: _____ Address: _____ Phone: _____ Fax: _____ Contact: _____	NPI: _____ NPI: _____ Tax ID: _____
--	---	--	---

PATIENT INFORMATION

Name: _____	<input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Trans M <input type="checkbox"/> Trans F <input type="checkbox"/> Other	DOB: ____/____/____	SS#: ____-____-____
Street: _____	City: _____	State: _____	ZIP: _____
Phone: _____	Alt. Phone: _____	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: _____	Wt.: _____ Ht.: _____


PRESCRIPTION

Has the patient received a loading dose/starter kit? <input type="checkbox"/> Yes Start Date: ____/____/____ <input type="checkbox"/> No SHIP TO: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Doctor's Office <input type="checkbox"/> Other: _____			
Drug	Directions & Quantity	Refills	
Adbry® <input type="checkbox"/> 150 mg Pre-filled Syringe*	<input type="checkbox"/> INITIAL: Inject 300 mg (two 150 mg injections) SQ at day 1 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 150 mg SQ every other week starting at day 15 (Quantity: 2)		
	<input type="checkbox"/> Take 100 mg PO once daily (Quantity: 30) <input type="checkbox"/> Take 200 mg PO once daily (Quantity: 30) ***Intended for patients who have not achieved adequate response with 100 mg daily dose***		
Cibinqo® <input type="checkbox"/> 100 mg Tablet* <input type="checkbox"/> 200 mg Tablet*	<input type="checkbox"/> Take 100 mg PO once daily (Quantity: 30) <input type="checkbox"/> Take 200 mg PO once daily (Quantity: 30) ***Intended for patients who have not achieved adequate response with 100 mg daily dose***		
	WEIGHT REQUIRED <input type="checkbox"/> Inject 300 mg SQ every 4 weeks (Quantity: 2) ***Intended for patients age 6 months to 5 years old weight 15 kg/33 lbs to <30 kg/66 lbs*** <input type="checkbox"/> INITIAL: Inject 600 mg SQ at day 1 (Quantity: 2) ***Intended for patients age 6 years to 17 years old weight 15 kg/33 lbs to <30 kg/66 lbs*** <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every 4 weeks starting at day 29 (Quantity: 2) <input type="checkbox"/> INITIAL: Inject 600 mg SQ at day 1 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2) ***Intended for weight ≥ 60 kg/132 lbs***		
Dupixent® <input type="checkbox"/> 300 mg Pre-filled Syringe <input type="checkbox"/> 300 mg Pen* <input type="checkbox"/> 200 mg Pre-filled Syringe <input type="checkbox"/> 200 mg Pen*	<input type="checkbox"/> Inject 200 mg SQ every 4 weeks (Quantity: 2) ***Intended for patients age 6 months to 5 years old weight 5 kg/11 lbs to <15 kg/33 lbs*** <input type="checkbox"/> INITIAL: Inject 400 mg SQ at day 1 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 200 mg SQ every other week starting at day 15 (Quantity: 2) ***Intended for weight 30 kg/66 lbs to < 60 kg/132 lbs***		
	<input type="checkbox"/> INITIAL: Inject 500 mg (two 250 mg injections) SQ at week 0 & week 2 (Quantity: 4) <input type="checkbox"/> INDUCTION: Inject 250 mg SQ every 2 weeks starting at week 4 (weeks 4-14) (Quantity: 2 plus 2 refills) <input type="checkbox"/> FINAL INDUCTION: Inject 250 mg SQ (week 16) (Quantity: 1) <input type="checkbox"/> MAINTENANCE: Inject 250 mg SQ every 4 weeks (thereafter) (Quantity: 1) <input type="checkbox"/> MAINTENANCE: Inject 250 mg SQ every 2 weeks (thereafter) (Quantity: 2)	***WEIGHT REQUIRED*** ***Intended for patients age 12 years and older weighing ≥ 40 kg/88 lbs***	
Eucrisa® <input type="checkbox"/> 2% Ointment 60 gm* <input type="checkbox"/> 2% Ointment 100 gm*	<input type="checkbox"/> Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)		

*Adbry/Dupixent pens/Cibinqo/Ebglyss FDA approved for ages 12 and older

*Eucrisa FDA approved for ages 3 months and older

MEDICAL INFORMATION

PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY			
PREVIOUS THERAPIES: <input type="checkbox"/> Methotrexate <input type="checkbox"/> Cyclosporine <input type="checkbox"/> Tacrolimus <input type="checkbox"/> Elidel <input type="checkbox"/> Protopic <input type="checkbox"/> _____	Tried & Failed (Duration): <input type="checkbox"/> (_____)	Not Tolerated: <input type="checkbox"/>	Contraindication: _____ _____ _____ _____ _____ _____
PHOTOTHERAPY <input type="checkbox"/> UVA /UVB <input type="checkbox"/> Patient cannot afford	Tried & Failed (Duration): <input type="checkbox"/> (_____)	Not Tolerated: <input type="checkbox"/>	Contraindication: <input type="checkbox"/> Distance from Office
<input type="checkbox"/> L20.9 Atopic Dermatitis <input type="checkbox"/> (Mild to Moderate) <input type="checkbox"/> (Moderate to Severe) <input type="checkbox"/> Other: _____			 <input type="checkbox"/> Face <input type="checkbox"/> Feet <input type="checkbox"/> Groin <input type="checkbox"/> Hands <input type="checkbox"/> Nails <input type="checkbox"/> Scalp <input type="checkbox"/> Other: Scoring tool used <input type="checkbox"/> BSA <input type="checkbox"/> EASI <input type="checkbox"/> ISGA <input type="checkbox"/> POEM <input type="checkbox"/> SCORAD _____ % or Score: Allergies: _____
Active TB is ruled out: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____ Hep B ruled out/treated: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____			

Additional Clinical Information:

INJECTION TRAINING

☐ Patient has received pen and injection training ☐ Physician's office to provide injection training ☐ Senderra to coordinate injection training

PRESCRIBER SIGNATURE

To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

Prescriber: _____	Date: ____/____/____
--------------------------	-----------------------------

CONFIDENTIALITY NOTICE

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.